Roland Buelow

Dr. Roland Buelow is a seasoned professional with nearly thirty years of experience in the biotechnology and pharmaceutical industries. He is renowned for his significant contributions and accomplishments in the field.

As the founder and CEO of Teneobio, Dr. Buelow leads a cutting-edge biotechnology company. Prior to this role, he founded and led Open Monoclonal Technology, Inc., a company that developed innovative technologies in the pharmaceutical sector, which was later acquired by Ligand Pharmaceuticals.

Dr. Buelow is also known for his involvement in THP, Inc., a biotechnology firm that specialized in engineering rabbits to produce human antibodies, eventually acquired by Roche. His career includes a tenure as the Senior Vice President of Research and Development at SangStat Medical Corporation, where he played a pivotal role in the development of RDP58, an anti-inflammatory compound with promising results in clinical trials.

Throughout his scientific journey spanning various prestigious institutions like Eberhard-Karls-University Tuebingen, the Max-Planck-Institute, Stanford University, and several biotech companies, Dr. Buelow has authored over 100 manuscripts and holds more than 30 patents, showcasing his innovative spirit and expertise in the domain.

Dr. Buelow's educational background is equally impressive, having studied Biology/Immunology at Stanford University, Biology at Max-Planck-Institut, and further academic pursuits at the University of Tübingen, shaping his profound knowledge and understanding in his field.